Parkinson's Disease
The latest sourced reporting on Parkinson's Disease from Dementias Today: dated, and plain about what the evidence does and does not show.
A narrative review published on October 20 inventories where generative AI already touches Alzheimer's work. The uses furthest along are the ones no family ever sees: synthetic notes, phenotype mining from visit records, and drafted summaries. None of it has been tested in a live clinic.
A phase 2 trial in early Parkinson's is testing dapansutrile, an oral NLRP3 inflammasome blocker, in people picked partly by a routine blood inflammation marker. The team's last immune trial, azathioprine, missed its primary outcome in December.
A February 2026 systematic review and meta-analysis of 17 sham-controlled brain stimulation trials in Parkinson's disease, 654 participants in total, found the sham response real but small, motor-specific, and stubbornly flat over time. Its authors argue the fix is in trial design, not in wishing expectation away.
A systematic review from the University of Leicester, published in Frontiers in Psychiatry on 8 May 2026, gathered thirteen experiments in which negative expectation was deliberately switched on in people living with long-term conditions. The symptoms that followed were real. What the review cannot tell you is what that means for a family managing dementia medicines.
A small feasibility study paired a 10-minute augmented reality and machine learning tablet test with clinician assessments in Parkinson's disease, catching every case of mild cognitive impairment that specialists confirmed but also flagging nearly half the group who did not have it.
A phase 2 randomized trial reports that repeated donor stool transplants outperformed transplants of patients' own stool on motor and constipation scores in drug-naive Parkinson's disease, the first controlled efficacy data since earlier reporting on gut changes that precede diagnosis.
A case-control study using a wearable ECG device found that several measures of heart rate variability were reduced in people with Parkinson's disease, and that one measure, low-frequency power, tracked tremor severity and correlated with brain volume on MRI. The pattern is different from the Alzheimer's-linked HRV changes reported earlier in this section, and the authors say it needs testing in far larger groups before it could serve as any kind of diagnostic tool.
A new review in Aging and Disease argues melatonin's value to the brain lies in timing, not sedation. The metric missing from most of the evidence is the one the argument depends on.
The STEM-PD trial, an academic program based at Lund University and the University of Cambridge, has published 12-month safety and feasibility results for an off-the-shelf dopamine progenitor cell product in eight people with Parkinson's disease, giving the field a second, independent line of early human evidence.
A prospective study of more than 48,000 UK Biobank participants found that lower heart-rate variability, measured from a brief resting ECG, was associated with a higher chance of developing Parkinson's disease over the next 12 years, with brain structure and inflammation markers offered as possible links.
A February 2026 Nature review by Henrik Zetterberg and Barbara Bendlin gathers the scattered story of blood and spinal fluid tests across Alzheimer's and other neurodegenerative dementias, and shows plainly where the map runs out.
A review in Alzheimer's & Dementia maps how falling NAD+ and the body's 24-hour timing machinery pull on each other in dementia. It is a map of mechanisms, not a treatment.
A machine learning pipeline called ActiTect flagged isolated REM sleep behavior disorder using only wrist-worn actigraphy, not an overnight sleep lab study, in a multi-cohort analysis published in npj Digital Medicine.
Two new studies measuring heart rate variability directly in people already diagnosed with Parkinson's disease link weaker nighttime autonomic signals to worse cognitive function and mood symptoms, moving the metric beyond predicting who gets diagnosed.
A global records analysis built to compare new melatonin users against new benzodiazepine and zolpidem users for dementia and Parkinson's disease outcomes found the reverse of the hoped-for result: melatonin starters had higher rates of diagnosis, not lower.
A new synthesis from Barcelona and London argues that brain aging is driven not only by misfolded protein, but by cells that have quit the cell cycle and will not stop signalling. It is a review, not a discovery, and the human evidence is still thin.
The Swiss team behind an actigraphy tool for spotting REM sleep behavior disorder has trained deep learning models on the same wrist recordings to separate Parkinson's disease patients from controls, and to test whether the same digital signature shows up early in isolated RBD.
A Chinese case-control study in eBioMedicine finds plasma metabolites that separate early Parkinson's from healthy controls, and two gut-derived molecules that rise with symptom severity. The model has not been tested outside the population that built it.
A peer-reviewed narrative review in Mechanisms of Ageing and Development argues that the ageing brain fails as a partnership, not as a single cell type: neurons, astrocytes, oligodendrocytes and microglia trading energy under the control of mitochondrial fission, fusion and mitophagy. It is a framework, not a finding, and it rests largely on animal and cell work.
Pooling 12 studies and more than 1,000 participants, researchers report the vagus nerve, the cable long theorized to carry disease-related protein from gut to brainstem, is on average thinner in people with Parkinson's disease than in those without it.
A Dutch laboratory trial found that openly telling healthy volunteers a device could not hurt them, paired with a symptom-reversing procedure, eased artificially induced pain sensitivity as well as or better than concealing that information. The method has not been tested in patients, older adults, or anyone with a dementia.
A Leiden-led systematic review finds the science of night-time wearables in Parkinson's disease so methodologically scattered that its intervention trials could not be pooled at all. The devices are already on wrists. The measuring rules are not yet written.
A Chinese team combined genetic analysis in people with experiments in mice and cells to argue that post-meal glucose spikes push dopamine neurons toward ferroptosis, an iron-dependent form of cell death. The human half of the evidence is genetic and indirect; the mechanism half is entirely animal and laboratory work.
A preprint from Regensburg, Aachen, Amsterdam and Imperial College London sets out how scans, blood markers and everyday speech could feed one patient-specific simulation. No patient has been through it, and the authors say bedside use comes last.
A review of 46 gut microbiome studies finds two bacterial genera rising and two falling in both healthy aging and Parkinson's disease, while one marker shifts only with the disease, a pattern researchers say could help separate age related change from disease specific risk.
Empatica's wearable platform, now carrying algorithms from the Personal KinetiGraph system it bought in 2025, won FDA clearance on August 14, 2026. The clearance is a finding of equivalence to existing devices, not proof the device changes anyone's care.
A preprint trains a 7 billion parameter reasoning model on the real hospital notes of roughly 3,000 patients, then asks it where the illness is heading. The work is retrospective and unreviewed, and it is franker about its own failure modes than most papers of its kind.
A review published online in Neurobiology of Disease on 23 September 2026 maps how neurons, astrocytes, oligodendrocytes, microglia and the brain's blood vessels split a very small energy budget, and argues that the breakdown of that split comes early in neurodegeneration, with neuronal loss as a late line in the account. It is a synthesis of work already published, with no new patient data.
Nine centres across North America are enrolling people whose dreams turn physical. There is no medicine in this study. Its purpose is to assemble the cohort that a future neuroprotection trial would need, and the scaffolding is the point.
Governor Kathy Hochul has signed a law forcing New York's long-term care hotline, NY Connects, to actively point callers toward Alzheimer's and dementia programs rather than leaving them to ask. The catch: nothing changes for a full year.
An open-access review in Advanced Healthcare Materials catalogues the nanoparticles engineered to carry drugs all the way to failing mitochondria in neurodegeneration, and states on its own first pages that none has been approved for anyone.
The National Institute for Health and Care Research has extended its Policy Research Unit at the University of Exeter with 2 million pounds and two extra years, stretching its mandate past dementia and neurodegeneration to cover more of the neurological conditions families live with.
Mission Therapeutics has dosed the first Parkinson's patient in a Phase 1b trial of MTX325, an oral drug designed to help brain cells clear out damaged mitochondria, a mechanism distinct from the amyloid and alpha-synuclein targets most other experimental drugs pursue, according to a new ClinicalTrials.gov registration and a company disclosure.
DemMA, published in the Findings of ACL 2026, puts a simulated person with dementia in the chair so trainees can practise the conversation: nine subtypes, nonverbal cues, 2,709 synthetic dialogues, and not one real patient in the data.
In the largest study yet to line up three stages of Parkinson's disease side by side overnight, researchers found that a faster resting heart rate during sleep tracked with lower cognitive test scores, a link that held even after accounting for age, education and motor severity.
A preprint reports that a pattern of brain network activity, read from a scan before anyone received treatment, tracked how strongly individual Parkinson's patients responded to placebo, first in a gene therapy trial and then in two more trials testing drugs by mouth and by injection.
A study of 42 Parkinson's patients in Fujian province found its own pattern of gut bacterial imbalance, the first look at this population and a check on whether a gut signature reported this year in Europe, the US, South Korea and Turkey shows up in people living on the other side of the world.
The Massachusetts House voted unanimously on July 29, 2026 to require acute care hospitals to notify a designated family member or caregiver soon after a dementia patient is admitted and again before discharge. The bill, which also expands diagnosis notification and creates a new MassHealth care coordination benefit, now heads to the Senate.
An 863-person imaging study published in Nature reports that the substantia nigra and all three major deep brain stimulation targets wire preferentially into a network that fuses thinking, body state and action, skipping the cortical strips that move a hand or a foot
Filed September 24 and still sitting in committee with Booker as its only sponsor, S.Res.910 points to an estimated 1.4 million Americans living with Lewy body dementia and asks for more research and better-trained clinicians. It carries no funding and no legal weight.
Block a receptor called P2X7, and a flood of inflammatory signaling in human brain cells and in tissue taken straight from neurosurgery recedes sharply. The scientists behind the finding call it a doorway toward future trials, not a drug sitting on a shelf today.
Twenty four patients, 28 days, one experimental pill aimed at a protein called LRRK2. The company that made it says the eye and spinal fluid changes it found are worth watching, and says plainly the study cannot tell us whether anyone got better.
A regional midterm review of the UN Decade of Healthy Aging finds that the share of countries in the Americas with a national long-term-care policy jumped from 61 percent to 88 percent since 2020, but the money and services to make those policies real have not kept pace, with direct consequences for how dementia care gets funded and staffed.
A national review of 1.15 million Parkinson's-related death certificates filed from 1999 through 2025 finds that the overall age-adjusted mortality rate did not change significantly over the full period, and that most of the apparent decline since 2021 traces to the fading effect of COVID-19 being listed alongside Parkinson's on death certificates, not to any improvement in underlying mortality.
Two Mount Sinai studies using engineered human brain tissue report that APOE4, the strongest genetic risk factor for Alzheimer's, drives a specific, experimentally reversible pattern of blood vessel scarring and protein buildup, distinct from the gene's broader population-level risk.
AbbVie's once-daily tablet, sold as JUVMO, is the first Parkinson's medicine built to act on D1 and D5 dopamine receptors rather than the D2/D3 pathway used by older agonists; the FDA's September 28 clearance covers both early monotherapy and add-on use for motor fluctuations.
A repeat survey of North American movement disorder clinicians finds barriers down and referrals up since the PD GENEration program began giving away panel testing. What it cannot show is that the program caused the change.
A quality improvement project at Oregon Health and Science University screened 405 family caregivers in a movement disorders clinic for burden and sent the highest scorers to a social worker; only a small fraction returned to be measured again.
The National Institute on Aging has published the finalized report from its fourth triennial Dementia Care and Caregiving Research Summit, naming five research areas and a list of gaps it wants filled next, including a fresh estimate that dementia now costs the country up to $800 billion a year.
TrueBinding's TB006, an antibody against galectin-3, has entered a placebo-controlled Phase 2a trial in early Parkinson's disease, according to its federal registration. The approach targets neuroinflammation rather than the alpha-synuclein clumping or kinase pathways most late-stage Parkinson's drugs pursue, and no human efficacy data in Parkinson's disease exist yet.
A Phase I/II study of UX-DA003, an injectable stem cell product made by Shanghai's UniXell Biotechnology, has been listed on ClinicalTrials.gov, joining rather than departing from the field's stem-cell efforts.
A new preprint from a Berkeley structural biology lab used cryo-electron tomography on cultured neurons and astrocytes and found no evidence that tau fibrils tear their way out of lysosomes. The compartments stayed intact. The leak, the authors argue, is something subtler. This is laboratory cell work, not peer reviewed, and not a treatment.
The ACTIVATE study of BIA 28-6156, an oral enzyme activator designed for Parkinson's patients carrying a GBA1 gene mutation, did not slow disease progression compared with placebo. Portuguese drugmaker Bial has stopped further development of the drug for this use.
At a national neurosciences institute in Bengaluru, an exploratory randomized trial is adding a 180-day Ayurvedic regimen to optimized standard Parkinson's care, then measuring cortical excitability, heart-rate variability, cytokines and telomere length. The protocol is now published. The results are not.
A laboratory study in Communications Biology reports that disease-linked chemical changes expose a normally hidden sticky region of alpha-synuclein, letting it grab other proteins indiscriminately, a mechanism the authors call a 'Multifactorial Random Disorder Model.'
Two newly built laboratory tests measuring the enzyme DOPA decarboxylase in spinal fluid distinguished Lewy body dementia and Parkinson's disease from Alzheimer's disease across several patient groups, a Nature Medicine study reports.
New open-label data presented at AD/PD 2026 extend a four-year Nature Medicine finding on prasinezumab, but the comparisons rest on an external cohort, not a placebo group, as the drug moves into phase III testing.
A phase 1 study delivered a single viral vector carrying both tyrosine hydroxylase and AADC genes into the striatum, aiming for cells that manufacture dopamine on their own rather than depending on oral levodopa. Twelve-month safety data are now published; the trial was not designed to prove the therapy works.
Peer reviewed 24 month data from a 12 person trial show sustained motor benefit from a single cell transplant, as a larger, sham controlled Phase 3 trial of the same therapy starts recruiting across three countries.
A peer-reviewed census of ClinicalTrials.gov registrations from 2015 to 2024 gives families a sourced map of what has actually been tested, including the handful of agents aimed at thinking and memory.